YTYing Tong

Ying Tong

*This is an algorithmically generated author record based on publicly available information.

Ying Tong has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Ang Li

    Shanghai Public Health Clinical Center, Shanghai Medical College, Fudan University, Shanghai, 201508, P. R. China

    1 shared publication
  • Baolong Zhang

    The Institutes of Biomedical Sciences (IBS) Fudan University Shanghai China

    1 shared publication
  • Ben Jia

    NHC Key Laboratory of Reproduction Regulation & Shanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Fudan University, Shanghai, China

    1 shared publication
  • Cancan Chen

    Shanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China

    1 shared publication
  • Cheng Lian

    Fudan University Shanghai Cancer Center 1 MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences , Shanghai, China

    1 shared publication
  • Daoping Ru

    Shanghai Public Health Clinical Center and Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute and Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China

    1 shared publication

Latest Publications

  • Living Donor Liver Transplantation for Patients With Hepatocellular Carcinoma: What Are the Optimal Criteria?

    by Meng Sha, Ying Tong, Qiang Xia

    We read with great interest the current issue by Bhangui P et al.(1) regarding the application of expanded selection criteria for living donor liver transplantation (LDLT) in patients with hepatocellular carcinoma (HCC). The authors incorporated alpha‐fetoprotein (AFP) and tumor FDG‐18 PET avidity into selection criteria and evaluated a total of 405 patients who underwent LDLT for HCC irrespective of tumor size and number.


  • Open Access

    Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network

    by Wei Li, Shuai Yang, Peng Xu, Dapeng Zhang, Ying Tong, Lu Chen, Ben Jia, Ang Li, Daoping Ru, Baolong Zhang, et al.

    SUMMARY: The COVID-19 pandemic is a widespread and deadly public health crisis. The pathogen SARS-CoV-2 replicates in the lower respiratory tract and causes fatal pneumonia. Although tremendous efforts have been put into investigating the pathogeny of SARS-CoV-2, the underlying mechanism of how SARS-CoV-2 interacts with its host is largely unexplored. Here, by comparing the genomic sequences of SARS-CoV-2 and human, we identified five fully conserved elements in SARS-CoV-2 genome, which were termed as “human identical sequences (HIS)”. HIS are also recognized in both SARS-CoV and MERS-CoV genome. Meanwhile, HIS-SARS-CoV-2 are highly conserved in the primate. Mechanically, HIS-SARS-CoV-2, behaving as virus-derived miRNAs, directly target to the human genomic loci and further interact with host enhancers to activate the expression of adjacent and distant genes, including cytokines gene and angiotensin converting enzyme II ( ACE2 ), a well-known cell entry receptor of SARS-CoV-2, and hyaluronan synthase 2 ( HAS2 ), which further increases hyaluronan formation. Noteworthily, hyaluronan level in plasma of COVID-19 patients is tightly correlated with severity and high risk for acute respiratory distress syndrome (ARDS) and may act as a predictor for the progression of COVID-19. HIS antagomirs, which downregulate hyaluronan level effectively, and 4-Methylumbelliferone (MU), an inhibitor of hyaluronan synthesis, are potential drugs to relieve the ARDS related ground-glass pattern in lung for COVID-19 treatment. Our results revealed that unprecedented HIS elements of SARS-CoV-2 contribute to the cytokine storm and ARDS in COVID-19 patients. Thus, blocking HIS-involved activating processes or hyaluronan synthesis directly by 4-MU may be effective strategies to alleviate COVID-19 progression.